Background: Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
Case Report: Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma.
Conclusion: These data show that re-biopsy in EGFR-mutated non-small cell lung cancer patients with acquired TKI resistance should be performed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000446759 | DOI Listing |
Publication Analysis
Top Keywords
epidermal growth
8
growth factor
8
factor receptor
8
rapid intracranial
4
intracranial response
4
response osimertinib
4
osimertinib patient
4
patient epidermal
4
receptor t790m-positive
4
t790m-positive adenocarcinoma
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!